Patients with primary progressive MS more commonly exhibited delays in overall disability progression following treatment with ocrelizumab vs placebo.
As they explained in their case report in the Journal of Neurology and Neuroscience, ophthalmologic examination identified ...
The new H-1B fee will “hurt the innovation and competitiveness of the U.S. industry,” says Subodha Kumar, a professor at the ...
Goldman Sachs is well-positioned to benefit from anticipated Fed rate cuts, fueling M&A, IPOs, and trading activity growth.
Discover how ClickUp and Monday.com enhance project management with integrations, automation, and collaboration. Compare ...
Recent advances in high-throughput microbiome profiling have generated expansive data sets that offer unprecedented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback